Kris V Kowdley

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.

E. Schiff, G. Everson, K. Kowdley, 2013, The New England journal of medicine.

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial.

K. Reddy, T. Hassanein, D. Dieterich, 2013, The Lancet. Infectious diseases.

Effectiveness of 8‐ or 12‐weeks of ledipasvir and sofosbuvir in real‐world treatment‐naïve, genotype 1 hepatitis C infected patients

B. Bacon, D. Dieterich, K. Kowdley, 2017, Alimentary pharmacology & therapeutics.